Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience

Xavier E Guerra-Torres; J Peña Esparragoza; M Perez Fernandez; M Fernandez Rodríguez; J Mancha Ramos; P Martinez Miguel; D Rodriguez Puyol; H Bouarich

Journal ArticleOPEN ACCESS

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience

Guerra-Torres X
Peña Esparragoza J
Perez Fernandez M
et al.

Cureus (2020)

DOI: 10.7759/cureus.10207

N/ACitations

10Readers

Abstract

Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the commonest inherited disorder of the kidneys. A vasopressin V2-receptor antagonist (tolvaptan) was recently approved for the treatment of ADPKD. This study aims to analyze the safety and tolerability of tolvaptan for the management of ADPKD patients in a real-world setting.

Cite

CITATION STYLE

APA

Guerra-Torres, X. E., Peña Esparragoza, J., Perez Fernandez, M., Fernandez Rodríguez, M., Mancha Ramos, J., Martinez Miguel, P., … Bouarich, H. (2020). Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience. Cureus. https://doi.org/10.7759/cureus.10207

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience

Abstract

Cite

Register to see more suggestions